Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Puey Ling Chia,1 Paul Mitchell,1 Alexander Dobrovic,2–4 Thomas John1,2,4 1Department of Medical Oncology, Olivia-Newton John Cancer and Wellness Centre, Victoria, Australia; 2Ludwig Institute for Cancer Research, Austin Health, Victoria, Australia; 3Department of Pathology, University of...
Main Authors: | Chia PL, Mitchell P, Dobrovic A, John T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-11-01
|
Series: | Clinical Epidemiology |
Online Access: | http://www.dovepress.com/prevalence-and-natural-history-of-alk-positive-non-small-cell-lung-can-peer-reviewed-article-CLEP |
Similar Items
-
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
by: Barrows SM, et al.
Published: (2019-02-01) -
ALK Inhibitors in the Treatment of ALK Positive NSCLC
by: Muhammad Khan, et al.
Published: (2019-01-01) -
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
by: David M. Waterhouse, et al.
Published: (2020-07-01) -
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01) -
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01)